LAGUNA HILLS, Calif., Dec. 21, 2017 – /Globe Newswire/ – Sonendo®, Inc., announced today the appointment of Michael Watts as Chief Financial Officer. Mr. Watts brings to Sonendo over 20 years of experience in financial operations and management in the medical device and healthcare industries.
“Michael’s experience in financial operations, management and strategy, along with his background serving life science companies are an ideal fit for Sonendo as we work to build on the positive momentum we are experiencing in 2017,” said Bjarne Bergheim, President and CEO of Sonendo.
Before joining Sonendo, Michael most recently served as Chief Financial Officer for The HydraFacial company, a leading manufacturer of non-invasive equipment and consumables used in aesthetic skin health treatments. Michael has held senior financial leadership positions with Johnson & Johnson, Zimmer Holdings, and Danaher Corporation. Early in his career, he spent five years as an auditor in public accounting and is a Certified Public Accountant (Massachusetts). Michael holds a Bachelor of Science degree in Accounting from the University of Massachusetts and Master of Science degree from Bentley College.
“I am extremely pleased to join Sonendo and committed to helping build on its success,” Watts said.
Sonendo, Inc. is a privately-held, venture-backed company developing innovative and disruptive technologies to transform dentistry by Saving Teeth Through Sound Science®. The first commercially available product from Sonendo, the GentleWave® System, available in the US, shows significant improvements in clinical efficacy and treatment efficiency when compared to standard root canal techniques.1,2 For more information, please visit www.sonendo.com.
1Sigurdsson A et al. (2016) J Endod. 42:1040-48. 2Molina B et al. (2015) J Endod. 41:1701-05.
This announcement contains forward-looking statements based on management's beliefs, assumptions and expectations and information currently available to management. All statements that address events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations on the timing and progress of research and development activities. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sonendo does not assume any obligation to update or revise any forward-looking statements publicly, whether as a result of new information, future events or otherwise. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.